• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use

by Jasmine Pennic 06/21/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use

What You Should Know: 

– Aranscia, a leader in personalized diagnostics, and Signature RX, a prominent pharmacy supplier, announced a collaborative effort to improve the effectiveness of GLP-1 medications. 

– The multi-phase partnership focuses on developing personalized treatment plans and ensuring consistent access to these crucial medications.

GLP-1s: Beyond Type 2 Diabetes

Glucagon-like peptide-1 receptor agonists (GLP-1s) were initially developed for type 2 diabetes management. However, their use has expanded to other chronic conditions like obesity. While many patients experience success with GLP-1s, individual responses vary in terms of efficacy, side effects, and long-term adherence. This variability can be attributed to unique metabolic responses.

Addressing Challenges in GLP-1 Therapy

The partnership aims to tackle these challenges through several key initiatives:

  • Precision Medicine for GLP-1s: Aranscia’s AccessDx Laboratory will dedicate resources to identifying novel biomarkers and pharmacogenomic (PGx) pathways specific to GLP-1 medications. They will collaborate with relevant organizations to conduct further research and establish frameworks based on these findings.
  • Personalized Medication Management: Signature RX will integrate Aranscia’s YouScript program into their existing offerings. YouScript leverages evidence-based PGx insights to optimize medication use and improve outcomes in patients with various chronic conditions, including those relevant to GLP-1 therapy.
  • Ensuring Medication Availability: The partnership aims to address current and projected shortages of GLP-1 medications, ensuring patients have consistent access to this critical treatment.

“We’re pleased to announce this innovative collaboration with Signature RX,” said Bryon Cipriani, CEO of Aranscia.  “The increasing popularity of GLP-1s, especially when unchecked against inappropriate or ineffective use, leads to runaway cost issues, supply chain challenges, and poor therapeutic outcomes that are detrimental to our care ecosystem.  We’re proud to make a commitment to the exploration of companion diagnostics with AccessDx Lab, and at the opportunity to leverage YouScript’s proven framework for success in personalized medication management.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |